ADAR1 Partners, LP 3/A
3/A · Acasti Pharma Inc. · Filed Jul 11, 2024
Insider Transaction Report
Form 3/AAmended
ADAR1 Capital Management, LLC
10% Owner
Holdings
- (indirect: By: ADAR1 Partners)
Common Warrant (Common Stock)
Exercise: $3.00From: 2023-09-25Exp: 2028-09-25→ Common Stock (1,268,195 underlying) - (indirect: By: ADAR1 Partners)
Pre-Paid Warrant (Common Stock)
Exercise: $0.00From: 2023-09-25→ Common Stock (913,631 underlying) - 959,571(indirect: By: ADAR1 Partners)
Class A Common Stock
Footnotes (5)
- [F1]ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners").
- [F2]ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners.
- [F3]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- [F4]Pursuant to a Pre-Funded Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 913,631 shares of Issuer's Common Stock, exercisable until fully filled.
- [F5]Pursuant to a Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 1,268,195 of Issuer's Common Stock.